Eye - diabetic macular oedema
The PBS subsidises aflibercept, dexamethasone intravitreal implant and ranibizumab for patients with diabetic macular oedema (DMO).
The PBS subsidises treatment with aflibercept, dexamethasone intravitreal implant and ranibizumab for patients with DMO. This is under Section 85 of the National Health Act 1953.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing aflibercept, dexamethasone intravitreal implant and ranibizumab.
To be eligible for PBS subsidised treatment with these medications, patients must be treated by:
- an ophthalmologist
- an accredited ophthalmology registrar in consultation with an ophthalmologist.
Applying for initial treatment
Apply for authority approval to prescribe initial PBS subsidised aflibercept, dexamethasone intravitreal implant and ranibizumab in writing and either:
All applications must include the completed:
- authority prescription form or forms
- Diabetic Macular Oedema Initial PBS authority application form (PB155)
- relevant attachments.
Applications to move between different drugs to treat DMO will require a new initial authority application to be completed.
Applying for continuing treatment
Applications for continuing authority applications to prescribe PBS subsidised aflibercept, dexamethasone intravitreal implant and ranibizumab can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Call the PBS Complex Drugs Programs enquiry line for further information.
Page last updated: 1 October 2020
This information was printed 11 September 2021 from https://www.servicesaustralia.gov.au/organisations/health-professionals/services/medicare/written-authority-required-drugs/drug-program-or-condition/eye-diabetic-macular-oedema. It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.servicesaustralia.gov.au/individuals/site-notices when using this material.